MetaCap

Innate Pharma S.A. ADS (IPHA)

NASDAQ: IPHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.8634-0.0765 (-8.14%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IPHA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$96.44M
EPS (TTM)
-$0.59
52-week range
0.829 – 2.71
Day range
0.829 – 0.9084
Volume / Avg
18.03K / 42.76K
Beta
—

52-week range

$0.829$2.71

IPHA stock today

Innate Pharma S.A. (IPHA) closed at $0.8634 on Nov 20, down 8.14% (-$0.0765), versus the S&P 500's 3.70% decline. Trading was light, with 18.03K shares changing hands, about 42% of the average daily volume. At this level, IPHA sits near the bottom of its 52-week range of $0.829 to $2.71: 68.1% below the high, set on Aug 13, 2026 and 4.1% above the low.

IPHA is down 50.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 52.6%. Innate Pharma S.A. has posted a net loss over the last twelve months (EPS of -$0.59), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Innate Pharma S.A.

Company profile

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Jonathan E. Dickinson B.Sc., M.B.A.
Headquarters
Marseille
Employees
120
IPO year
2019

Analyst forecast

Forecast

Consensus (3 analysts)

buy

Avg. price target

$8.00+826.57%

  • Strong buy 0
  • Buy 2
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $7.00High $9.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

IPHA news

All IPHA news

Innate Pharma S.A. peers

Health Care sector
IPHA peer companies
CompanyPrice% ChgMarket capCompare
MOLNMolecular Partners AG ADR2.53-5.25%$96.80Mvs IPHA
VYGRVoyager Therapeutics Inc.1.53-4.97%$95.21Mvs IPHA
OTLKOutlook Therapeutics Inc.0.39-2.74%$94.94Mvs IPHA
LENZLENZ Therapeutics Inc.2.97-11.23%$93.16Mvs IPHA
ZURAZura Bio Limited Class A0.9305-2.30%$89.63Mvs IPHA
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs IPHA
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs IPHA
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs IPHA

Indexes, lists and sector

Innate Pharma S.A. stock FAQ

What is Innate Pharma S.A.'s stock price today?

IPHA last traded at $0.8634 as of Nov 20, 4:00 PM EST, down 8.14% on the day. Prices are delayed at least 15 minutes.

Who is Innate Pharma S.A.'s CEO?

Mr. Jonathan E. Dickinson B.Sc., M.B.A. is the chief executive officer of Innate Pharma S.A. ADS, which has about 120 employees.

What is the IPHA 52-week high?

The 52-week high for IPHA is $2.71 and the 52-week low is $0.829. The stock is currently 68.1% below its high.

Compare IPHA